SCHEMBL20511322

SCHEMBL20511322

Cc1cccc(/C=N/Nc2cc(N3CCOCC3)n3nc(-c4ccncc4)nc3n2)c1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIKFYVE Q9Y2I7 11/20 0.76
KDM4E B2RXH2 4/20 0.56
MAPT P10636 4/20 0.56
LMNA P02545 3/20 0.56
HPGD P15428 1/20 0.56
FES P07332 1/20 0.49
FER P16591 1/20 0.49
TYK2 P29597 1/20 0.49
FRK P42685 1/20 0.49
SYK P43405 1/20 0.49
CAMK1D Q8IU85 1/20 0.49
IRAK4 Q9NWZ3 1/20 0.49
ATM Q13315 1/20 0.44
ALDH1A1 P00352 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31089726 1.00 PIKFYVE (0.76) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL20511324 1.00 PIKFYVE (0.76) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL20511333 0.91 PIKFYVE (0.65) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL20511365 0.89 PIKFYVE (0.61) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL20511300 0.89 PIKFYVE (0.61) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL31089708 0.89 PIKFYVE (0.61) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL20511360 0.89 PIKFYVE (0.61) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL20511305 0.89 PIKFYVE (0.61) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL31089693 0.89 PIKFYVE (0.61) PIKFYVEKDM4EMAPTLMNAHPGD
SCHEMBL20511320 0.89 PIKFYVE (0.60) PIKFYVEKDM4EMAPTLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294536-A1 FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION PIKSCI INC. (CA) 2024-09-05 US disclosed
US-11987583-B2 Fused triazolo-pyrimidine compounds having useful pharmaceutical application PIKSCI INC. (CA) 2024-05-21 US disclosed
US-20240016810-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS YUMANITY THERAPEUTICS, INC. 2024-01-18 US disclosed
WO-2021252895-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS YUMANITY THERAPEUTICS, INC. (US) 2021-12-16 WO disclosed
US-20210323969-A1 FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION PIKSCI INC. (CA) 2021-10-21 US disclosed
US-20210323969-A1 FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION PIKSCI INC. (CA) 2021-10-21 US disclosed
US-11066410-B2 Fused triazolo-pyrimidine compounds having useful pharmaceutical application 3100 CENTRAL EXPRESSWAY LLC (US) 2021-07-20 US disclosed
US-11066410-B2 Fused triazolo-pyrimidine compounds having useful pharmaceutical application 3100 CENTRAL EXPRESSWAY LLC (US) 2021-07-20 US disclosed
US-20200079780-A1 FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION NANOSYN, INC. 2020-03-12 US disclosed
EP-3600328-A1 FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION Nanosyn, Inc. (US) 2020-02-05 EP disclosed
WO-2018175906-A1 FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION NANOSYN, INC. (US) 2018-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016810-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS TARDBP, PIKFYVE, FUS PIKFYVE 2/4885KDM4E 788/4885MAPT 33/4885
US-11987583-B2 Fused triazolo-pyrimidine compounds having useful pharmaceutical application PIKFYVE, PIP4K2B, PIP4K2A PIKFYVE 1/4885KDM4E 1042/4885MAPT 2023/4885
US-20210323969-A1 FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION PIKFYVE, PIP4K2B, PIP4K2A PIKFYVE 1/4885KDM4E 1042/4885MAPT 2023/4885
US-11066410-B2 Fused triazolo-pyrimidine compounds having useful pharmaceutical application PIKFYVE, PIP4K2B, PIP4K2A PIKFYVE 1/4885KDM4E 1042/4885MAPT 2023/4885
US-20200079780-A1 FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION PIKFYVE, PIP4K2B, PIP4K2A PIKFYVE 1/4885KDM4E 1042/4885MAPT 2023/4885
US-20240294536-A1 FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION PIKFYVE, PIP4K2B, PIK3CA PIKFYVE 1/4885KDM4E 536/4885MAPT 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.